表紙
市場調查報告書

共軛疫苗的全球市場:2020年∼2024年

Conjugate Vaccines Market by Type and Geography - Forecast and Analysis 2020-2024

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 920029
出版日期 內容資訊 英文 151 Pages
訂單完成後即時交付
價格
Back to Top
共軛疫苗的全球市場:2020年∼2024年 Conjugate Vaccines Market by Type and Geography - Forecast and Analysis 2020-2024
出版日期: 2019年12月10日內容資訊: 英文 151 Pages
簡介

全球共軛疫苗市場上,疫苗開發的資金籌措增加,疫苗接種計劃和疫苗的獲取相關認識,及共軛疫苗的認證和法規上的獎勵等成為成長促進因素,在預測期間內預計將以超越9%的年複合成長率擴大。但,由於疫苗的研究,開發,及製造相關的高成本,共軛疫苗相關的安全性疑慮,及共軛疫苗的開發與全球性實行的課題等要素,可能妨礙在預測期間內共軛疫苗產業的成長。

本報告提供全球共軛疫苗市場相關調查分析,市場規模及成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 親市場
  • 市場特徵
  • 價值鏈分析
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2019年)
  • 市場預測
  • 市場規模及預測(2019年∼2024年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 市場區隔:各類型

  • 市場區隔:各類型
  • 各類型比較:市場規模及預測(2019年∼2024年)
  • 多價共軛疫苗
  • 一價共軛疫苗
  • 市場機會:各類型

第7章 客戶形勢

第8章 各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2019年∼2024年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第9章 決策架構

第10章 成長要素與課題

  • 市場成長要素
  • 市場課題

第11章 市場趨勢

  • 新共軛疫苗開發的研究活動的增加
  • 改善共軛疫苗製造的策略的出現
  • 共軛疫苗貯存的努力增加

第12章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭方案

第13章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Aurobindo Pharma Ltd.
  • GlaxoSmithKline Plc
  • Integrated Biotherapeutics Inc.
  • Merck & Co. Inc.
  • 田邊三菱製藥
  • Pfenex Inc.
  • Pfizer Inc.
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Sun Pharmaceutical Industries Ltd.

第14章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第15章 關於TECHNAVIO

目錄
Product Code: IRTNTR40714

About this market

Technavio's conjugate vaccines market analysis considers sales from the multivalent conjugate vaccine and monovalent conjugate vaccine types. Our study also finds the sales of conjugate vaccines in Asia, Europe, North America, and ROW. In 2019, the multivalent conjugate vaccine segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the prevention of diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive diseases will play a significant role in the multivalent conjugate vaccine segment to maintain its market position. Also, our global conjugate vaccines market report looks at factors such as increased funding for vaccine development, awareness about immunization programs and access to vaccines, and approval and regulatory incentives for conjugated vaccines. However, high costs associated with vaccine research, development, and manufacturing, safety concerns associated with conjugate vaccines, and challenges in development and global implementation of conjugate vaccines hamper the growth of the conjugate vaccines industry over the forecast period.

Overview

Increasing awareness about immunization programs and access to vaccines

Initiatives aimed at increasing the awareness about well recognized and successful public health immunization programs are promoting the overall vaccine coverage around the globe. For instance, World Pneumonia Day is celebrated every year on November 12 to lower the incidence of pneumonia and reduce the resultant mortality rate. Similarly, other programs are focusing on improving drug delivery and diagnostics to address the health issues in low and middle-income countries. Such initiatives targeted towards boosting access to vaccines will drive the demand for conjugate vaccines. Conjugate vaccines are developed to immunize against a single antigen or two or more strains of the same microorganism. Thus, the promotion of immunization programs will lead to the expansion of the global conjugate vaccines market at a CAGR of over 9% during the forecast period.

Increasing efforts for stockpiling of conjugate vaccines

Governments are putting efforts to store vaccines in bulk to combat future emergency outbreaks of infectious diseases. For instance, The United Nations Children's Fund (UNICEF) works in collaboration with several public and private organizations to procure vaccines to combat future emergency outbreaks of infectious diseases. Furthermore, the International Coordinating Group (ICG) on Vaccine Provisions for Epidemic Meningitis Control also unites several public and private organizations to support emergency health programs and disease outbreak programs. The ongoing efforts in this area are expected to present significant growth opportunities for the existing vendors to meet the unmet demand for meningococcal conjugate vaccines, which will support the growth of the market during the forecast period.

For the detailed list of factors that will drive the global conjugate vaccines market during the forecast period 2020-2024, view our report.

Competitive Landscape

With the presence of a few major players, the global conjugate vaccines market is concentrated. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading conjugate vaccines manufacturers, that include Aurobindo Pharma Ltd., GlaxoSmithKline Plc, Integrated Biotherapeutics Inc., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corp., Pfenex Inc., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., and Sun Pharmaceutical Industries Ltd.

Also, the conjugate vaccines market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Parent market
  • Market characteristics
  • Value Chain Analysis
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2019
  • Market Outlook
  • Market size and forecast 2019-2024

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Multivalent conjugate vaccine - Market size and forecast 2019-2024
  • Monovalent conjugate vaccine - Market size and forecast 2019-2024
  • Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Increasing research activities for novel conjugate vaccine development
  • Emergence of strategies to improve conjugate vaccine manufacturing
  • Increasing efforts for stockpiling of conjugate vaccines

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Aurobindo Pharma Ltd.
  • GlaxoSmithKline Plc
  • Integrated Biotherapeutics Inc.
  • Merck & Co. Inc.
  • Mitsubishi Tanabe Pharma Corp.
  • Pfenex Inc.
  • Pfizer Inc.
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Sun Pharmaceutical Industries Ltd.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

LIST OF EXHIBITS:

  • Exhibit 01: Global pharmaceuticals market
  • Exhibit 02: Segments of global pharmaceuticals market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Vendors: Key offerings
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2019
  • Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
  • Exhibit 10: Five forces analysis 2019
  • Exhibit 11: Five forces analysis 2024
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2019
  • Exhibit 18: Type - Market share 2019-2024 (%)
  • Exhibit 19: Comparison by type
  • Exhibit 20: Multivalent conjugate vaccine - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 21: Multivalent conjugate vaccine - Year-over-year growth 2020-2024 (%)
  • Exhibit 22: Monovalent conjugate vaccine - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 23: Monovalent conjugate vaccine - Year-over-year growth 2020-2024 (%)
  • Exhibit 24: Market opportunity by type
  • Exhibit 25: Customer landscape
  • Exhibit 26: Market share by geography 2019-2024 (%)
  • Exhibit 27: Geographic comparison
  • Exhibit 28: North America - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 29: North America - Year-over-year growth 2020-2024 (%)
  • Exhibit 30: Top 3 countries in North America
  • Exhibit 31: Europe - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 32: Europe - Year-over-year growth 2020-2024 (%)
  • Exhibit 33: Top 3 countries in Europe
  • Exhibit 34: Asia - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 35: Asia - Year-over-year growth 2020-2024 (%)
  • Exhibit 36: Top 3 countries in Asia
  • Exhibit 37: ROW - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 38: ROW - Year-over-year growth 2020-2024 (%)
  • Exhibit 39: Top 3 countries in ROW
  • Exhibit 40: Key leading countries
  • Exhibit 41: Market opportunity
  • Exhibit 42: Impact of drivers and challenges
  • Exhibit 43: Vendor landscape
  • Exhibit 44: Landscape disruption
  • Exhibit 45: Vendors covered
  • Exhibit 46: Vendor classification
  • Exhibit 47: Market positioning of vendors
  • Exhibit 48: Aurobindo Pharma Ltd. - Vendor overview
  • Exhibit 49: Aurobindo Pharma Ltd. - Business segments
  • Exhibit 50: Aurobindo Pharma Ltd. - Organizational developments
  • Exhibit 51: Aurobindo Pharma Ltd. - Geographic focus
  • Exhibit 52: Aurobindo Pharma Ltd. - Key offerings
  • Exhibit 53: Aurobindo Pharma Ltd. - Key customers
  • Exhibit 54: GlaxoSmithKline Plc - Vendor overview
  • Exhibit 55: GlaxoSmithKline Plc - Business segments
  • Exhibit 56: GlaxoSmithKline Plc - Organizational developments
  • Exhibit 57: GlaxoSmithKline Plc - Geographic focus
  • Exhibit 58: GlaxoSmithKline Plc - Segment focus
  • Exhibit 59: GlaxoSmithKline Plc - Key offerings
  • Exhibit 60: GlaxoSmithKline Plc - Key customers
  • Exhibit 61: Integrated Biotherapeutics Inc. - Vendor overview
  • Exhibit 62: Integrated Biotherapeutics Inc. - Business segments
  • Exhibit 63: Integrated Biotherapeutics Inc. - Key offerings
  • Exhibit 64: Integrated Biotherapeutics Inc. - Key customers
  • Exhibit 65: Merck & Co. Inc. - Vendor overview
  • Exhibit 66: Merck & Co. Inc. - Business segments
  • Exhibit 67: Merck & Co. Inc. - Organizational developments
  • Exhibit 68: Merck & Co. Inc. - Geographic focus
  • Exhibit 69: Merck & Co. Inc. - Segment focus
  • Exhibit 70: Merck & Co. Inc. - Key offerings
  • Exhibit 71: Merck & Co. Inc. - Key customers
  • Exhibit 72: Mitsubishi Tanabe Pharma Corp. - Vendor overview
  • Exhibit 73: Mitsubishi Tanabe Pharma Corp. - Business segments
  • Exhibit 74: Mitsubishi Tanabe Pharma Corp. - Organizational developments
  • Exhibit 75: Mitsubishi Tanabe Pharma Corp. - Geographic focus
  • Exhibit 76: Mitsubishi Tanabe Pharma Corp. - Key offerings
  • Exhibit 77: Mitsubishi Tanabe Pharma Corp. - Key customers
  • Exhibit 78: Pfenex Inc. - Vendor overview
  • Exhibit 79: Pfenex Inc. - Business segments
  • Exhibit 80: Pfenex Inc. - Organizational developments
  • Exhibit 81: Pfenex Inc. - Key offerings
  • Exhibit 82: Pfenex Inc. - Key customers
  • Exhibit 83: Pfizer Inc. - Vendor overview
  • Exhibit 84: Pfizer Inc. - Business segments
  • Exhibit 85: Pfizer Inc. - Organizational developments
  • Exhibit 86: Pfizer Inc. - Geographic focus
  • Exhibit 87: Pfizer Inc. - Segment focus
  • Exhibit 88: Pfizer Inc. - Key offerings
  • Exhibit 89: Pfizer Inc. - Key customers
  • Exhibit 90: Sanofi - Vendor overview
  • Exhibit 91: Sanofi - Business segments
  • Exhibit 92: Sanofi - Organizational developments
  • Exhibit 93: Sanofi - Geographic focus
  • Exhibit 94: Sanofi - Segment focus
  • Exhibit 95: Sanofi - Key offerings
  • Exhibit 96: Sanofi - Key customers
  • Exhibit 97: Serum Institute of India Pvt. Ltd. - Vendor overview
  • Exhibit 98: Serum Institute of India Pvt. Ltd. - Product segments
  • Exhibit 99: Serum Institute of India Pvt. Ltd. - Organizational developments
  • Exhibit 100: Serum Institute of India Pvt. Ltd. - Key offerings
  • Exhibit 101: Serum Institute of India Pvt. Ltd. - Key customers
  • Exhibit 102: Sun Pharmaceutical Industries Ltd. - Vendor overview
  • Exhibit 103: Sun Pharmaceutical Industries Ltd. - Business segments
  • Exhibit 104: Sun Pharmaceutical Industries Ltd. - Organizational developments
  • Exhibit 105: Sun Pharmaceutical Industries Ltd. - Geographic focus
  • Exhibit 106: Sun Pharmaceutical Industries Ltd. - Key offerings
  • Exhibit 107: Sun Pharmaceutical Industries Ltd. - Key customers
  • Exhibit 108: Validation techniques employed for market sizing
  • Exhibit 109: Definition of market positioning of vendors
Back to Top